Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion
For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?